false 0001829802 0001829802 2024-10-25 2024-10-25 0001829802 us-gaap:CommonStockMember 2024-10-25 2024-10-25 0001829802 us-gaap:SeriesAPreferredStockMember 2024-10-25 2024-10-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 25, 2024

 

 

Sensei Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-39980   83-1863385
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

1405 Research Blvd, Suite 125

Rockville, MD

   20850
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (240) 243-8000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

  

Trading
symbol

  

Name of each exchange
on which registered

Common Stock   SNSE   The Nasdaq Stock Market LLC
Series A Preferred Stock Purchase Rights     The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 25, 2024, Deneen Vojta, MD notified the Chair of the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) of her decision to resign from the Board, effective December 31, 2024. Her resignation was due to personal reasons and not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Sensei Biotherapeutics, Inc.
Date: October 30, 2024      

/s/ Christopher W. Gerry

      Christopher W. Gerry
      General Counsel and Secretary

 

3

v3.24.3
Document and Entity Information
Oct. 25, 2024
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001829802
Document Type 8-K
Document Period End Date Oct. 25, 2024
Entity Registrant Name Sensei Biotherapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39980
Entity Tax Identification Number 83-1863385
Entity Address, Address Line One 1405 Research Blvd
Entity Address, Address Line Two Suite 125
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code (240)
Local Phone Number 243-8000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock
Trading Symbol SNSE
Security Exchange Name NASDAQ
Series A Preferred Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Series A Preferred Stock Purchase Rights
Security Exchange Name NASDAQ
Sensei Biotherapeutics (NASDAQ:SNSE)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Sensei Biotherapeutics.
Sensei Biotherapeutics (NASDAQ:SNSE)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Sensei Biotherapeutics.